The Post-Partisan Emporium

 Can't wait to see the outcome of the DOUBLE m[iracle]RNA jabs COVIDIUS+mFLUsiva once available...     If you want go   here   to the FDA Briefing Document BLA# 125869/0 Influenza Vaccine, mRNA (Proposed Trade Name: mFlusiva) Applicant: Moderna TX, Inc. Vaccines and Related Biological Products Advisory Committee (VRBPAC) June 18, 2026, feel free! Just don't call it "my own research"!   From the above 'here': "FDA Assessment: The temporal distribution of deaths from unspecified causes does not suggest a causal relationship to vaccination.", does it EVER?!   See... SAFE & EFFECTIVE, just like with the Sisters! voza0db.substack.com   Mere coinkydink... do carry on! voza0db.substack.com And a little Weekend FUN...  

It seems that some Japanese crazy people want to blame m[iracle]RNA toxic spew COVIDIUS jabs to EXCESS DEATHS! Crazy gang...   From CANADA...ei,  Passing from Portugal...  It seems that the Japs are being fooled! Persistent   All- Cause   Excess   Mortality   Observed   in   Japan   After   the   COVID- 19   Pandemic Seiji Kojima   * , Miki Gibo , Kenji Fujikawa Abstract Introduction: Following the end of the COVID-19 pandemic, excess mortality rates declined in many countries. However, Japan’s excess mortality rate remained elevated even in 2024. Most countries have stopped administering booster vaccines on a large scale; however, Japan continues to recommend COVID-19 vaccination for elderly individuals, and its booster vaccination per capita rate is the highest in the world. This study attempted to identify the variables related to excess mortality rates during and after the pandemic.Methods: The age-adjusted n...

       

CRACKS FORMING? Japan, I understand, is a funny place. “Face” is very important over there, and as a consequence folks tend not to get heated but rather shy away from confrontation. Certainly yelling is pretty much unheard of. In a public environment, even less so. And in a public place WITH cameras rolling it really does stand out. Which is one reason why it’s interesting to witness Japanese Emeritus Professor, Dr Fukushima from Kyoto University and Chairman of Translational Research Informatics Center lose his isht. Here, at 4:49 minutes speaking on  Rumble . He is clearly livid. This  biography  lists him as an infectious diseases expert.  He is an oncologist with over 25 years’ experience and therefore well qualified to speak on the subject. This video has been shared widely across social media platforms, but I understand that  it’s not broken into the Japanese MSM. Meanwhile … That right there is a very punchable face. Just saying. So what does the CEO of t...

Molnupiravir, developed by Merck & Co. Inc. and Ridgeback Biotherapeutics LP - Oct. 26, 2021.  The COVID-19 antiviral drug Molnupiravir helps speed up recovery from the virus but does not reduce the hospitalization or death rate in higher-risk vaccinated adults, a new study has found. Molnupiravir, from Ridgeback Biotherapeutics and Merck & Co. is used to treat mild to moderate COVID-19 and can be taken at home, twice a day for five days, within five days of symptoms onset. It works by stopping the virus from replicating, keeping levels low in the body, thus reducing its severity. The study was published in The Lancet on Dec. 22 and has been peer reviewed. For more tedious reading go to the source ***** This is the FUN part of the paper: In conclusion, this trial of vaccinated adults at increased risk of an adverse outcome and unwell with confirmed SARS-CoV-2 infection showed that early treatment with molnupiravi...